Corporis Medical

Founded in 2015 and headquartered in Maastricht, Netherlands, Corporis Medical develops innovative medical devices that enhance minimally invasive surgical outcomes, focusing on wound closure and tissue monitoring. Corporis Medical specializes in creating medical devices aimed at improving surgical procedures. The company was founded in 2015 in Maastricht, Netherlands, by Alexander Veenhof. It has successfully completed 3 deals, including its latest funding round, Series B, which raised EUR 4.

000 mn led by Unorthodox Ventures alongside other investors like Brightlands Venture Partners and Industriebank LIOF. The total amount raised by the company stands at EUR 4. 000 mn. Corporis Medical specializes in the development and commercialization of innovative medical devices aimed at enhancing outcomes in minimally invasive surgery.

The company's core offerings include the Mediclose System and the Laprixa System. The Mediclose System is a single-use suturing device designed specifically for the percutaneous suturing of port-site fascia wounds following laparoscopic procedures. This device addresses the need for efficient and effective wound closure in minimally invasive surgeries. The Laprixa System, recognized as the world's smallest tissue blood pressure measurement device, provides a means to objectively assess tissue wound healing capacity in a quantitative and patient-specific manner.

These products are targeted primarily at surgical hospitals and clinics across Europe and North America, with end users including surgeons and healthcare professionals who require reliable tools for improved patient outcomes. Corporis Medical's revenue model is structured around direct sales to healthcare institutions and surgical centers, focusing on its flagship products, the Mediclose and Laprixa Systems. The transactions typically involve a B2B approach, where hospitals and clinics purchase these medical devices as part of their surgical supplies. Pricing strategies for these products are determined based on the specific needs of the healthcare institutions and the scale of their operations.

Each product is sold as a single-use item, appealing to hospitals that prioritize hygiene and efficiency in surgical procedures. By catering to a specialized market, Corporis Medical positions itself to generate consistent revenue through repeat purchases by healthcare providers reliant on innovative solutions for patient care. Corporis Medical plans to launch new products aimed at further enhancing surgical outcomes. Specific details regarding upcoming product releases have not been disclosed.

The company is focusing on expanding its market reach across Europe and North America, aiming to tap into new healthcare sectors by the end of 2024. The recent funding from Inkef will be allocated towards supporting product development and market expansion initiatives.